United Therapeutics (UTHR): Goldman Says Sell As The Base Business Shrinks, But 2027 Holds Real Catalysts
Goldman Sachs initiated coverage of United Therapeutics (UTHR) with a Sell rating and $321 price target, citing shrinking core business and challenges in IPF launch. Q2 revenue fell 2% to $783.3M, missing expectations. Tyvaso revenue dropped 18%, while Tyvaso DPI grew 4%. Earnings rose due to tax benefits and share buybacks. FDA review for IPF application is due April 2027. Hedge fund ownership increased, with shares trading at 16.4x forward earnings.
How this was made
The 30-second read
Why it matters
The downgrade and $321 price target introduce a fresh negative catalyst, likely prompting short‑term selling pressure.
Market read
New analyst coverage provides actionable insight for traders; the negative stance may influence UTHR's price trajectory in the near term.
What to watch
Potential upside from upcoming FDA decisions in 2027 could offset short‑term concerns.
Background
Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics (UTHR) with a Sell rating, highlighting a shrinking core franchise and challenges for the upcoming IPF product launch.
Ticker impact
Goldman Sachs initiated coverage with a Sell rating and $321 price target, citing a shrinking base business and a hard IPF launch.
likely pressure as the market prices in the sell rating and concerns over a slower base business.
Analyst downgrade with a specific price target provides a clear near‑term trade signal.
Market effects
Biotech/Pharma sector may see heightened scrutiny on IPF pipeline companies.
U.S. biotech stocks could face modest sell pressure.
Limited to investors tracking biotech earnings and analyst coverage.
Counterpoint
If the IPF launch proceeds as planned, the sell rating may be premature.
Key entities
- companyUnited Therapeutics Corporation
Biopharma firm developing IPF and PAH therapies.
- analyst_firmGoldman Sachs
Issued the Sell rating and price target.
